Philips Reports Strong Q2 2024 Performance with Order Growth and Margin Improvement

Strong Order Intake and Margin Improvement

Philips, the renowned Dutch health technology company, has reported a strong performance in the second quarter of 2024. The company experienced a significant 9% comparable order intake growth, driven by double-digit growth in both its Diagnosis & Treatment and Connected Care businesses 1

1

. This growth demonstrates the increasing demand for Philips' innovative healthcare solutions and technologies.

Financial Highlights

The company's adjusted EBITA margin showed a notable improvement, reaching 10.5% of sales. This represents a 390 basis points increase compared to the same period last year 2

2

. The enhanced profitability can be attributed to Philips' ongoing productivity measures and pricing strategies.

Group sales for the quarter amounted to EUR 4.5 billion, reflecting a 9% comparable sales growth. This growth was primarily driven by the Connected Care businesses, which experienced double-digit growth 1

1

. The company's ability to maintain strong sales growth in a challenging economic environment underscores the resilience of its business model and the relevance of its product portfolio.

Segment Performance

The Diagnosis & Treatment segment, which includes medical imaging and diagnostic equipment, showed robust performance with double-digit order intake growth 2

2

. This indicates a strong market demand for Philips' advanced diagnostic solutions and a potential increase in healthcare infrastructure investments globally.

Connected Care, encompassing patient monitoring and respiratory care solutions, was a standout performer with double-digit growth in both order intake and sales 1

1

. This segment's success can be attributed to the ongoing need for advanced patient care technologies in hospitals and healthcare facilities worldwide.

Strategic Initiatives and Outlook

Philips' CEO, Roy Jakobs, expressed satisfaction with the company's performance, stating that the strong order intake growth and margin expansion demonstrate the effectiveness of their strategy 2

2

. The company remains focused on executing its plan to create value with sustainable impact in healthcare technology.

Looking ahead, Philips has confirmed its full-year 2024 outlook. The company expects 3-5% comparable sales growth and an Adjusted EBITA margin of 10-11% for the full year 1

1

. This positive outlook reflects the company's confidence in its ability to navigate market challenges and capitalize on growth opportunities in the healthcare technology sector.

Conclusion of Philips Recall Program

Importantly, Philips has completed its Respironics recall notification program for sleep therapy devices 2

2

. This marks a significant milestone in addressing previous product safety concerns and reinforces the company's commitment to patient safety and product quality.